LivaNova PLC — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
LivaNova reported Q2 2026 revenue of $390.6M (up 10.8% reported, 9.8% constant-currency) and raised full-year revenue guidance to 8–9% constant-currency growth (from 7–8%) and adjusted diluted EPS to $4.30–$4.40 (from $4.20–$4.30). The company signed a long-term supply agreement with Thermo Fisher Scientific for critical oxygenator components to expand manufacturing capacity. Cash flow guidance was lowered to $140–160M (from $160–180M) due to strategic capacity investments. A €81.8M ($95.4M) discrete tax benefit from Italian tax authority ruling on SNIA environmental liability deductibility was also recognized.
Why this rating
Meaningful guidance raise (100bps revenue, $0.10 EPS midpoint) and strategic supply agreement are significant for a $2.5B company; tax benefit is material but one-time; offset by lower FCF guidance and capacity investment costs.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.